Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease

Alqalyoobi, Shehabaldin; Adegunsoye, Ayodeji; Linderholm, A.; Hrusch, Cara L.; Cutting, Claire C.; Fan, Shwu; Sperling, Anne I.; Noth, Imre; Strek, Mary E.; Oldham, Justin M.

doi:10.1164/rccm.201907-1343le

Cited by 34 publications

(24 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…116,117 High MMP-7 levels in HP have been linked with reduced survival. 118 In patients with SSc-ILD, increased serum levels of MMP-12 appear to correlate with decreased FVC, and raised levels of tissue inhibitor of MMP-1 are associated with decreased DLCO. 119 High levels of circulating fibrocytes have been associated with reduced lung function and an increased risk of ILD-associated mortality.…”

Section: Prognostic Biomarkersmentioning

confidence: 94%

Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype

Inoue

Kaner

Guiot

et al. 2020

Chest

View full text Add to dashboard Cite

Biomarkers have the potential to become central to the clinical evaluation and monitoring of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.Here we summarize the current understanding of putative serum, BAL fluid, and genetic biomarkers in this setting, according to their hypothesized pathobiologic mechanisms: evidence of epithelial cell dysfunction (eg, Krebs von den Lungen-6 antigen), fibroblast proliferation and extracellular matrix production or turnover (eg, matrix metalloproteinase-1), or immune dysregulation (eg, CC chemokine ligand 18). While most of the available data come from idiopathic pulmonary fibrosis (IPF), the prototypic progressive fibrosing ILD, data are available in the broader patient population of chronic fibrosing ILDs. A number of these biomarkers show promise, however, none have been validated. In this review article, we assess both the status of proposed biomarkers for chronic fibrosing lung diseases with a progressive phenotype in predicting disease risk or predisposition, diagnosis, prognosis, and treatment response and provide a direct comparison between IPF and other chronic fibrotic ILDs. We also reflect on the current clinical usefulness and future direction of research for biomarkers in the setting of chronic fibrosing ILDs with a progressive phenotype.

show abstract

Section: Prognostic Biomarkersmentioning

confidence: 94%

Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype

Inoue

Kaner

Guiot

et al. 2020

Chest

View full text Add to dashboard Cite

show abstract

“…Collectively, these findings suggest that patients with PF-ILD are at high risk for acute exacerbations. Recent studies have demonstrated the promise of specific blood biomarkers in predicting the risk of progression, acute exacerbations and mortality in patients with IPF and other PF-ILD, but additional prospective studies are needed to validate these findings and confirm their clinical utility [35,36].…”

Section: Risk Factors For Progressionmentioning

confidence: 99%

Progression of fibrosing interstitial lung disease

2020

View full text Add to dashboard Cite

Fibrotic interstitial lung diseases (ILDs) are often challenging to diagnose and classify, but an accurate diagnosis has significant implications for both treatment and prognosis. A subset of patients with fibrotic ILD experience progressive deterioration in lung function, physical performance, and quality of life. Several risk factors for ILD progression have been reported, such as male sex, older age, lower baseline pulmonary function, and a radiological or pathological pattern of usual interstitial pneumonia. Morphological similarities, common underlying pathobiologic mechanisms, and the consistently progressive worsening of these patients support the concept of a progressive fibrosing (PF)-ILD phenotype that can be applied to a variety of ILD subtypes. The conventional approach has been to use antifibrotic medications in patients with idiopathic pulmonary fibrosis (IPF) and immunosuppressive medications in patients with other fibrotic ILD subtypes; however, recent clinical trials have suggested a favourable treatment response to antifibrotic therapy in a wider variety of fibrotic ILDs. This review summarizes the literature on the evaluation and management of patients with PF-ILD, and discusses questions relevant to applying recent clinicial trial findings to real-world practice.

show abstract

“…Biomarkers for ILDs are essential and would offer clinicians the ability to provide evidence-based personalized care to ILD patients. Currently, the application of ILD biomarkers is hindered by the complexity of ILD diagnostic criteria [ 81 , 82 , 119 , 120 , 121 ]. The main obstacles are the sensitivity and specificity of such biomarkers that require high case numbers for statistical validation.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic and Therapeutic Applications of Extracellular Vesicles in Interstitial Lung Diseases

Ibrahim¹,

Ibrahim

Parimon

2021

Diagnostics

View full text Add to dashboard Cite

Interstitial lung diseases (ILDs) are chronic irreversible pulmonary conditions with significant morbidity and mortality. Diagnostic approaches to ILDs are complex and multifactorial. Effective therapeutic interventions are continuously investigated and explored with substantial progress, thanks to advances in basic understanding and translational efforts. Extracellular vesicles (EVs) offer a new paradigm in diagnosis and treatment. This leads to two significant implications: new disease biomarker discovery that enables reliable diagnosis and disease assessment and the development of regenerative medicine therapeutics that target fibroproliferative processes in diseased lung tissue. In this review, we discuss the current understanding of the role of diseased tissue-derived EVs in the development of interstitial lung diseases, the utility of these EVs as diagnostic and prognostic tools, and the existing therapeutic utility of EVs. Furthermore, we review the potential therapeutic application of EVs derived from various cellular sources.

show abstract

Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease

Cited by 34 publications

References 10 publications

Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype

Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype

Progression of fibrosing interstitial lung disease

Diagnostic and Therapeutic Applications of Extracellular Vesicles in Interstitial Lung Diseases

Contact Info

Product

Resources

About